Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs

Executive Summary

Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.

You may also be interested in...



European Nod For Roche’s Ocrevus Clouded By Patient Limitation

Swiss major Roche has finally got a positive opinion for its closely watched drug but concerns have been raised that Ocrevus will only be licensed for early-stage primary progressive multiple sclerosis patients.

Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

Topics

UsernamePublicRestriction

Register

SC099803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel